CA2300362A1 - Coat-protein-modified baculovirus vector for gene therapy - Google Patents
Coat-protein-modified baculovirus vector for gene therapy Download PDFInfo
- Publication number
- CA2300362A1 CA2300362A1 CA002300362A CA2300362A CA2300362A1 CA 2300362 A1 CA2300362 A1 CA 2300362A1 CA 002300362 A CA002300362 A CA 002300362A CA 2300362 A CA2300362 A CA 2300362A CA 2300362 A1 CA2300362 A1 CA 2300362A1
- Authority
- CA
- Canada
- Prior art keywords
- vector
- sequence
- vector according
- dna sequence
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013598 vector Substances 0.000 title claims abstract description 60
- 241000701447 unidentified baculovirus Species 0.000 title claims abstract description 33
- 238000001415 gene therapy Methods 0.000 title claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 241000238631 Hexapoda Species 0.000 claims abstract description 12
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 9
- 101710094648 Coat protein Proteins 0.000 claims abstract description 9
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims abstract description 9
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 9
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 9
- 101710083689 Probable capsid protein Proteins 0.000 claims abstract description 9
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 7
- 230000014509 gene expression Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 108010009575 CD55 Antigens Proteins 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 2
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 3
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010055167 CD59 Antigens Proteins 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101710146216 Membrane cofactor protein Proteins 0.000 claims 1
- 102000048238 Neuregulin-1 Human genes 0.000 claims 1
- 108090000556 Neuregulin-1 Proteins 0.000 claims 1
- 102000015215 Stem Cell Factor Human genes 0.000 claims 1
- 108010039445 Stem Cell Factor Proteins 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 14
- 238000012546 transfer Methods 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 238000010276 construction Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19735593.5 | 1997-08-15 | ||
| DE1997135593 DE19735593C2 (de) | 1997-08-15 | 1997-08-15 | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie |
| PCT/DE1998/002255 WO1999009193A1 (de) | 1997-08-15 | 1998-08-05 | Hüllprotein-modifizierter baculovirus-vektor für die gentherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2300362A1 true CA2300362A1 (en) | 1999-02-25 |
Family
ID=7839201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002300362A Abandoned CA2300362A1 (en) | 1997-08-15 | 1998-08-05 | Coat-protein-modified baculovirus vector for gene therapy |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1003896A1 (de) |
| JP (1) | JP2003530064A (de) |
| CA (1) | CA2300362A1 (de) |
| DE (1) | DE19735593C2 (de) |
| ES (1) | ES2150894T1 (de) |
| WO (1) | WO1999009193A1 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6183993B1 (en) * | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
| GB0012997D0 (en) * | 2000-05-26 | 2000-07-19 | Eurogene Limited | Gene delivery |
| WO2002014527A2 (en) | 2000-08-11 | 2002-02-21 | Boyce Thompson Institute For Plant Research, Inc. | Gp64-null baculoviruses pseudotyped with heterologous envelope proteins |
| WO2002072853A1 (en) * | 2001-03-12 | 2002-09-19 | Ark Therapeutics Limited | Avidin-pseudotyped viral vectors and their use |
| WO2002096469A2 (en) * | 2001-05-29 | 2002-12-05 | Ark Therapeutics Ltd. | Gene delivery via a baculovirus vector |
| GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| US6863884B2 (en) | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
| US7416890B2 (en) | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
| AU2003266628A1 (en) * | 2002-09-25 | 2004-04-19 | Osaka Industrial Promotion Organization | Baculovirus vector, method of constructing baculovirus vector and gene transfer method |
| CN103755800B (zh) | 2004-02-02 | 2016-02-24 | Ambrx公司 | 经修饰的人类生长激素多肽与其用途 |
| AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
| CN102532321B (zh) | 2004-06-18 | 2018-10-12 | Ambrx公司 | 新颖抗原结合多肽和其用途 |
| US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| GB0425739D0 (en) * | 2004-11-23 | 2004-12-22 | Procure Therapeutics Ltd | Humanised baculovirus 2 |
| US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
| AU2005323106B2 (en) | 2004-12-22 | 2010-07-29 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
| KR101224781B1 (ko) | 2004-12-22 | 2013-01-21 | 암브룩스, 인코포레이티드 | 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물 |
| NZ555425A (en) | 2004-12-22 | 2010-04-30 | Ambrx Inc | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| WO2006133088A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| CA2618878C (en) | 2005-08-18 | 2016-06-28 | Ambrx, Inc. | Compositions of trna and uses thereof |
| EP1951890A4 (de) | 2005-11-16 | 2009-06-24 | Ambrx Inc | Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
| ES2457527T3 (es) | 2006-09-08 | 2014-04-28 | Ambrx, Inc. | ARNt Supresor hibrido en células de vertebrados |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| KR20100019467A (ko) | 2007-05-02 | 2010-02-18 | 암브룩스, 인코포레이티드 | 변형된 인터페론 베타 폴리펩티드 및 그의 용도 |
| ES2632504T3 (es) | 2007-11-20 | 2017-09-13 | Ambrx, Inc. | Polipéptidos de insulina modificados y sus usos |
| NZ602170A (en) | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| MX2011000859A (es) | 2008-07-23 | 2011-02-24 | Ambrx Inc | Polipeptidos g-csf bovinos modificados y sus usos. |
| NO2337846T3 (de) | 2008-09-26 | 2018-06-16 | ||
| PL2342223T3 (pl) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania |
| NZ600361A (en) | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
| EP2516455A4 (de) | 2009-12-21 | 2013-05-22 | Ambrx Inc | Modifizierte schweine-somatotropin-polypeptide und deren verwendungen |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| WO2016059911A1 (ja) * | 2014-10-17 | 2016-04-21 | 国立大学法人金沢大学 | マラリアワクチン |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4407859C1 (de) * | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vektor für die leberspezifische Gentherapie |
| EP0785803A4 (de) * | 1994-09-23 | 2000-08-02 | Gen Hospital Corp | Gebrauch eines nicht-säuger dna virus zur expression eines exogenen gens in einer säugetierzelle |
| US5750383A (en) * | 1996-05-14 | 1998-05-12 | Boyce Thompson Institute For Plant Research, Inc. | Baculovirus cloning system |
-
1997
- 1997-08-15 DE DE1997135593 patent/DE19735593C2/de not_active Expired - Fee Related
-
1998
- 1998-08-05 WO PCT/DE1998/002255 patent/WO1999009193A1/de not_active Ceased
- 1998-08-05 CA CA002300362A patent/CA2300362A1/en not_active Abandoned
- 1998-08-05 ES ES98947386T patent/ES2150894T1/es active Pending
- 1998-08-05 JP JP2000509856A patent/JP2003530064A/ja active Pending
- 1998-08-05 EP EP98947386A patent/EP1003896A1/de not_active Withdrawn
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
| US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
| US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
| US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
| US12247058B2 (en) | 2014-10-24 | 2025-03-11 | Bristol-Myers Squibb Company | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
| US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
| US12097241B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides |
| US12097242B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003530064A (ja) | 2003-10-14 |
| EP1003896A1 (de) | 2000-05-31 |
| WO1999009193A1 (de) | 1999-02-25 |
| DE19735593A1 (de) | 1999-02-18 |
| ES2150894T1 (es) | 2000-12-16 |
| DE19735593C2 (de) | 1999-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2148934C (en) | Targetable vector particles | |
| JP2003530064A (ja) | 遺伝子治療用のコートタンパク質改変バキュロウイルス−ベクター | |
| JP3681752B2 (ja) | 遺伝子治療に使用できる宿主 − ベクタ系 | |
| EP0851769B1 (de) | Gentherapie mit hilfe von schaf-adenoviralen vektoren | |
| US6905678B2 (en) | Gene delivery vectors with cell type specificity for mesenchymal stem cells | |
| US6872528B2 (en) | Highly productive packaging lines | |
| WO2001058940A2 (en) | Adenoviral capsid containing chimeric protein ix | |
| NZ515582A (en) | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 | |
| JP2001522236A (ja) | 改変アデノウイルスファイバーおよび標的アデノウイルス | |
| AU2002315947A1 (en) | Adenoviral vectors with cell type specificity for mesenchymal cells | |
| AU717202B2 (en) | New variants of apolipoprotein A-I | |
| US6635466B2 (en) | Adenovirus serotype 30 (Ad30) | |
| US5736360A (en) | Endothelial cell tropic compositions and methods of making and using the same | |
| AU729934B2 (en) | Retroviral vector and its use in gene therapy | |
| WO1998047916A1 (en) | Bifunctional polypeptides for cell-specific viral targeting | |
| US20040146487A1 (en) | Avidin pseudotyped viral vectors and their use | |
| AU747763B2 (en) | Method for helper virus-free packaging of a gene vector DNA | |
| EP1279738A1 (de) | Für mesenchymale Stammzellen spezifische Gen-Transfer-Vektoren | |
| CA2131415C (en) | Vector for liver-specific gene therapy | |
| US20020137213A1 (en) | Adenovirus particles with mutagenized fiber proteins | |
| EP1195440A1 (de) | Genverabreichung-Vektoren für Stammzellen | |
| CA2047363C (en) | Recombinant therapies for infection and hyperproliferative disorders | |
| EP0870050A2 (de) | Toxisches protein exprimierende viren und produktionszellinien | |
| Lea et al. | The Scope of Viral Vectors for the Transduction of Haemopoietic Cells | |
| CA2229515A1 (en) | Expression of a foamy virus envelope protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |